Active substanceAtropineAtropine
Similar drugsTo uncover
  • Atropine
    drops d / eye 
  • Atropine
    solution for injections 
  • Atropin Nova
    solution for injections 
    JODAS EKSPOIM, LLC     Russia
  • Atropine sulfate
    solution for injections 
    DALHIMFARM, OJSC     Russia
  • Atropine sulfate
    solution for injections 
  • Dosage form: & nbspinjection
    Composition:

    1 ml of the solution contains 1 mg or 0.5 mg of atropine sulfate.

    Excipients: hydrochloric acid, water for injection.

    Description:Transparent colorless liquid.
    Pharmacotherapeutic group:M-holinoblokator
    ATX: & nbsp

    A.03.B.A   Alkaloids belladonna, tertiary amines

    A.03.B.A.01   Atropine

    Pharmacodynamics:

    The alkaloid contained in the plants of the Solanaceae family, the blocker of M-cholinergic receptors, binds equally to the m1, m2 and m3 subtypes of muscarinic receptors. Affects both central and peripheral M-holinoretseptory. It also acts (though much weaker) on n-cholinergic receptors. Prevents the stimulating effect of acetylcholine; reduces the secretion of salivary, gastric, bronchial, lacrimal, sweat glands, pancreas. Reduces the tone of the muscles of the internal organs (bronchi, digestive tract, bile duct and gallbladder, urethra, bladder); causes tachycardia, improves AV conductivity.Reduces motility of the gastrointestinal tract, practically does not affect the secretion of bile. It dilates the pupils, hinders the outflow of the intraocular fluid, increases the intraocular pressure, causes paralysis of accommodation. In average therapeutic doses, it has a stimulating effect on the central nervous system and a delayed but prolonged sedative effect; stimulates breathing (high doses - respiratory paralysis). Excites the cerebral cortex (in high doses), in toxic doses causes excitation, agitation, hallucinations, coma. Reduces the tone of the vagus nerve, which leads to an increase in heart rate (with a slight change in blood pressure) and a slight increase in conductivity in the bundle. The effect is more pronounced with initially increased tone of the vagus nerve.

    After IV introduction, the maximum effect is manifested after 2-4 minutes, after oral administration (in the form of drops) - after 30 minutes.

    Pharmacokinetics:

    Widely distributed in the body. Metabolised in the liver by enzymatic hydrolysis. The connection with plasma proteins is 18%. Penetrates through the blood-brain barrier, the placenta and into breast milk. In significant concentrations found in the central nervous system after 0.5-1 h. The half-life period is 2 h.

    Kidney excretion - 50% unchanged, the rest - in the form of products of hydrolysis and conjugation.

    Indications:

    Exacerbation of peptic ulcer of the stomach and duodenum; acute pancreatitis; pilorospasm; spasms of the intestine, gallbladder and bile ducts, urinary tract, bronchi; laryngospasm (prevention); hypersalivation (Parkinsonism, poisoning with salts of heavy metals); bradycardia; AV blockade; poisoning with cholinomimetic and anticholinesterase agents; premedication before surgical operations.

    Contraindications:

    Hypersensitivity, zakratougolnaya glaucoma or predisposition to it, tachyarrhythmias, severe congestive heart failure, ischemic heart disease, mitral stenosis, reflux esophagitis, hepatic and / or renal failure, intestinal atony, myasthenia gravis, prostatic hyperplasia, obstructive bowel disease, paralytic ileus, toxic megacolon, ulcerative colitis, hernia of the esophageal opening of the diaphragm.

    Carefully:

    Hyperthermia, arterial hypertension. Hyperthyroidism, age over 40 years (risk of undiagnosed glaucoma).

    Pregnancy and lactation:

    Atropine penetrates the placental barrier. Adequate and strictly controlled clinical studies of the safety of atropine during pregnancy have not been conducted. With intravenous administration of the drug during pregnancy or shortly before the birth it is possible to develop tachycardia in the fetus.

    It is not prescribed during pregnancy, complicated by gestosis, tk. can lead to an increase in blood pressure. The use of the drug in the period of breastfeeding is contraindicated.

    Dosing and Administration:

    For relief of acute pain in stomach ulcer and duodenal ulcer and pancreatitis, renal, hepatic colic, etc. The drug is administered SC or IM in 0.25 -1 mg (0.25-1 ml solution).

    To eliminate bradycardia - in / in 0.5 to 1 mg, if necessary, after 5 minutes, the administration can be repeated.

    For the purpose of premedication - in / m 0,4 - 0,6 mg for 45 - 60 minutes before anesthesia.

    Children the drug is administered in a dose of 0.01 mg / kg.

    When poisoning with m-cholinostimulants and anticholinesterase agents, 1.4 ml 0,1% IV solution (syringe tube), preferably in combination with cholinesterase reagents.

    Side effects:

    Dry mouth, tachycardia, headache, dizziness, atony of the intestine and bladder, constipation, difficulty urinating, photophobia, mydriasis, accommodation paralysis, increased intraocular pressure, xerostomia, impaired tactile perception.

    Overdose:

    Symptoms. Dryness of the mucous membrane of the oral cavity and nasopharynx, violation of swallowing and speech, dry skin, hyperthermia, mydriasis, etc. (see section "Side effect"); motor and speech excitation, memory impairment, hallucinations, psychosis.

    Treatment. Anticholinesterase and sedatives.

    Interaction:

    Weaken the effect of m-cholinomimetics and anticholinesterase agents. Diphenhydramine or promethazine - strengthening the effect of atropine.

    Nitrates increase the likelihood of increased intraocular pressure.

    Procainamide is an increase in anticholinergic action.

    Under the influence of guanethidine, a decrease in the hypoxecretory effect of atropine is possible.

    Effect on the ability to drive transp. cf. and fur:During the treatment period, it is necessary to refrain from driving and other potentially hazardous activities,requiring increased concentration of attention and speed of psychomotor reactions.
    Form release / dosage:

    Solution for injection 0.05% or 0.1%.

    Packaging:

    1 ml per ampoule of neutral glass.

    For 10 ampoules, together with the instruction for use and the ampoule opening opener or ampoule scarifier, is placed in a cardboard box.

    When using ampoules with notches, rings and break points, the ampoule opener opener or ampoule scarifier is allowed not to be inserted.

    5 ampoules per contour cell packaging made of polyvinylchloride film and aluminum foil lacquered or foil-free. For 1 or 2 contour mesh packages along with the instruction for use are placed in a pack of cardboard.

    Storage conditions:

    Store in a dark place at a temperature of 2 to 30 ° C.

    Keep out of the reach of children.
    Shelf life:5 years. Do not use after the expiry date printed on the package.
    Terms of leave from pharmacies:On prescription
    Registration number:P N002652 / 01
    Date of registration:21.04.2008 / 13.05.2014
    Expiration Date:Unlimited
    The owner of the registration certificate:DALHIMFARM, OJSC DALHIMFARM, OJSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp20.09.2017
    Illustrated instructions
      Instructions
      Up